Endoscopy 2011; 43(8): 697-701
DOI: 10.1055/s-0030-1256467
Original article

© Georg Thieme Verlag KG Stuttgart · New York

Comparative study of bipolar eletrocoagulation versus argon plasma coagulation for rectal bleeding due to chronic radiation coloproctopathy

L.  Lenz1 , 2 , J.  Tafarel1 , L.  Correia1 , D.  Bonilha1 , M.  Santos1 , R.  Rodrigues1 , 2 , G.  Gomes1 , G.  Andrade1 , 3 , F.  Martins1 , 3 , M.  Monaghan4 , F.  Nakao1 , 2 , E.  Libera1 , 2 , A.  P.  Ferrari1 , 3 , R.  Rohr1 , 2
  • 1Endoscopy Unit, Universidade Federal de São Paulo, Brazil
  • 2Fleury Medicina e Saúde, Centro de Medicina Diagnóstica, São Paulo, Brazil
  • 3Endoscopy, Hospital Israelita Albert Einstein, São Paulo, Brazil
  • 4King’s College London School of Medicine, London, United Kingdom
Further Information

Publication History

submitted 13 June 2010

accepted after revision 2 March 2011

Publication Date:
24 May 2011 (online)

Zoom Image

Background and study aim: Chronic radiation coloproctopathy (CRCP) is a well-recognized complication of radiotherapy, with rectal bleeding the most common presentation. It is frequently refractory to conservative management, but the optimal endoscopic treatment of bleeding secondary to CRCP is still controversial. The efficacy and safety of bipolar eletrocoagulation (BEC) and argon plasma coagulation (APC) in the management of bleeding from CRCP were evaluated and compared.

Patients and methods: 30 patients (mean age 67.4 years) with active and chronic bleeding from telangiectasias, were randomly allocated to BEC or APC and stratified by severity of CRCP according to clinical severity and endoscopic findings (Saunders score). Success was defined as eradication of all telangiectasias, and therapeutic failure as need for more than seven sessions or for other treatment. Complications were categorized as minor (e. g. fever, anal or abdominal pain) or major (hemorrhagic).

Results: Both treatments were equally effective for the treatment of CRCP rectal bleeding. Only one failure was observed in each group (P = 1.000). There was no significant difference between the two groups regarding number of sessions, minor or major complications, or relapse. However, overall complication rate was significantly higher in the BEC group (P = 0.003).

Conclusions: BEC and APC are both effective for the therapy of bleeding telangiectasias from CRCP. There are probably no major differences between them. Although APC seemed safer than BEC in this investigation, further studies, involving a much larger population, are needed to assess the complication rates and determine the best management option.